Preisler Barbara, Pezeshkpoor Behnaz, Banchev Atanas, Fischer Ronald, Zieger Barbara, Scholz Ute, Rühl Heiko, Kemkes-Matthes Bettina, Schmitt Ursula, Redlich Antje, Unal Sule, Laws Hans-Jürgen, Olivieri Martin, Oldenburg Johannes, Pavlova Anna
Institute of Experimental Hematology and Transfusion Medicine, University Clinic Bonn, 53127 Bonn, Germany.
Department of Paediatric Haematology and Oncology, University Hospital "Tzaritza Giovanna-ISUL", 1527 Sofia, Bulgaria.
J Clin Med. 2021 Jan 18;10(2):347. doi: 10.3390/jcm10020347.
Familial multiple coagulation factor deficiencies (FMCFDs) are a group of inherited hemostatic disorders with the simultaneous reduction of plasma activity of at least two coagulation factors. As consequence, the type and severity of symptoms and the management of bleeding/thrombotic episodes vary among patients. The aim of this study was to identify the underlying genetic defect in patients with FMCFDs.
Activity levels were collected from the largest cohort of laboratory-diagnosed FMCFD patients described so far. Genetic analysis was performed using next-generation sequencing.
In total, 52 FMCFDs resulted from coincidental co-inheritance of single-factor deficiencies. All coagulation factors (except factor XII (FXII)) were involved in different combinations. Factor VII (FVII) deficiency showed the highest prevalence. The second group summarized 21 patients with FMCFDs due to a single-gene defect resulting in combined FV/FVIII deficiency or vitamin K-dependent coagulation factor deficiency. In the third group, nine patients with a combined deficiency of FVII and FX caused by the partial deletion of chromosome 13 were identified. The majority of patients exhibited bleeding symptoms while thrombotic events were uncommon.
FMCFDs are heritable abnormalities of hemostasis with a very low population frequency rendering them orphan diseases. A combination of comprehensive screening of residual activities and molecular genetic analysis could avoid under- and misdiagnosis.
家族性多种凝血因子缺乏症(FMCFDs)是一组遗传性止血障碍性疾病,血浆中至少两种凝血因子的活性同时降低。因此,患者的症状类型和严重程度以及出血/血栓形成事件的处理方式各不相同。本研究的目的是确定FMCFDs患者潜在的基因缺陷。
从迄今为止描述的最大一组实验室诊断的FMCFDs患者中收集活性水平数据。使用下一代测序进行基因分析。
总共有52例FMCFDs是由单因子缺乏症的巧合共同遗传导致的。所有凝血因子(除因子Ⅻ(FXII)外)都以不同组合参与其中。因子Ⅶ(FVII)缺乏症的患病率最高。第二组总结了21例因单基因缺陷导致FV/FVIII联合缺乏或维生素K依赖凝血因子缺乏的FMCFDs患者。在第三组中,鉴定出9例因13号染色体部分缺失导致FVII和FX联合缺乏的患者。大多数患者表现出出血症状,而血栓形成事件并不常见。
FMCFDs是遗传性止血异常,人群发病率极低,属于罕见病。综合筛查残余活性和分子遗传学分析相结合可避免漏诊和误诊。